Drug giant Bristol-Myers Squibb announced a deal to buy hepatitis C drug developer Inhibitex Inc. for $26 a share, or more than $2 billion.
WSJ.com: US Business, Wall Street Journal: Business
Sat, 01/07/2012 - 7:58pm
Drug giant Bristol-Myers Squibb announced a deal to buy hepatitis C drug developer Inhibitex Inc. for $26 a share, or more than $2 billion.